RT Journal Article
SR Electronic
T1 COPD and risk of cardiovascular disease: A prospective study of 0.5M Chinese adults
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA614
DO 10.1183/13993003.congress-2015.PA614
VO 46
IS suppl 59
A1 Om Kurmi
A1 Liming Li
A1 Kourtney Davis
A1 Jenny Wang
A1 Ling Yang
A1 Yiping Chen
A1 Yu Guo
A1 Zheng Bian
A1 Rory Collins
A1 Richard Peto
A1 Zhengming Chen
YR 2015
UL http://erj.ersjournals.com/content/46/suppl_59/PA614.abstract
AB Background: Chronic Obstructive Pulmonary Disease (COPD) is associated with co-morbidities in hospital-based data, but evidence from large population based prospective cohorts from low and middle income countries is sparse.Aims: To investigate the risk of incident cardiovascular (CV) events by COPD status in a large Chinese cohort.Methods: A population-based prospective study recruited over 0.5M adults aged 30-79 during 2004-08 from 10 areas across China with mean 7 years of follow-up from recruitment until December 2013 through linkage to death certificates, disease registries and hospital records. Participants without self-reported physician diagnosis of CV diseases (n=489382), stratified by prevalent COPD (physician or spirometry diagnosed) were analysed and Cox proportional hazard model was used to yield adjusted hazard ratios (HR) for CV events comparing individuals with and without prior COPD.Results: Overall 8.5% had COPD at baseline and they tended to be older, underweight, regular smokers and of lower socio-economic status (SES) compared to non-COPD individuals. Prevalence of CV events varied amongst those with COPD at baseline: haemorrhagic stroke (HS) (1.5%), major coronary events (MCE) (1.2%), CV mortality (2.6%) and congestive heart failure (CHF) (5.3%). COPD was associated with an increased risk of HS (HR=1.22, 95% CI 1.12-1.33), MCE (1.34, 1.21-1.48), CV mortality (1.30, 1.22-1.39) and CHF (1.95, 1.67-2.28). The excess risk among people with prior COPD varied little by sex, age and area.Conclusions: COPD was independently associated with an increased risk of CV events. COPD detection and management should be integrated with CV disease risk reduction efforts.(Funded by GSK).